Campbell & Co Investment Adviser’s ANI Pharmaceuticals ANIP Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,805	Closed	-$2.27M	–	1054
2025 Q4	$2.27M	Buy	28,805 +11,366	+65%	+$984K	0.11%	288
2025 Q3	$1.6M	Buy	+17,439	New	+$1.42M	0.12%	254
2019 Q4	–	Sell	-5,875	Closed	-$428K	–	645
2019 Q3	$428K	Buy	5,875 +1,796	+44%	+$134K	0.16%	237
2019 Q2	$335K	Sell	4,079 -4,797	-54%	-$341K	0.15%	264
2019 Q1	$626K	Buy	+8,876	New	+$522K	0.31%	70
2018 Q3	–	Sell	-4,072	Closed	-$272K	–	392
2018 Q2	$272K	Buy	+4,072	New	+$254K	0.21%	226
2017 Q4	–	Sell	-8,334	Closed	-$437K	–	386
2017 Q3	$437K	Buy	+8,334	New	+$397K	0.35%	81

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Campbell & Co Investment Adviser's ANIP Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 28,805 shares — an estimated $2.27M sold.

Campbell & Co Investment Adviser first reported a position in ANIP in Q3 2017 and held it in 7 quarters. The position peaked at $2.27M in Q4 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 28,805 ANI Pharmaceuticals shares in Q1 2026, an estimated $2.27M.
Campbell & Co Investment Adviser first reported a position in ANI Pharmaceuticals in Q3 2017 and held it in 7 quarters.
Campbell & Co Investment Adviser's ANI Pharmaceuticals position peaked at $2.27M in Q4 2025.
281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.